Outcome MeasureAnxiety

STAI

State-Trait Anxiety Inventory

19 Papers in Blossom

About This Instrument

The State-Trait Anxiety Inventory (STAI) is a 40-item self-report measure developed by Charles Spielberger that distinguishes between temporary state anxiety (how anxious you feel right now, Form Y-1, 20 items) and enduring trait anxiety (how anxious you generally feel, Form Y-2, 20 items). Each item is rated on a 1–4 scale, producing subscale scores of 20–80. The STAI is one of the most cited anxiety instruments in psychology and has been used extensively in psychedelic research, including the landmark Johns Hopkins and NYU psilocybin studies for cancer-related distress. The state anxiety subscale is particularly useful for measuring acute anxiety during or immediately after psychedelic sessions, while the trait subscale captures lasting anxiolytic effects. The STAI has excellent reliability (α > 0.90) and extensive normative data across diverse populations.

Clinical Thresholds

2080
Low anxiety
Score 2037
Moderate
Score 3844
High anxiety
Score 4580

Outcome Data Across Studies

Reported results for STAI across 9 studies with quantitative data.

Outcome data across 31 study arm–timepoint observations
SD
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
2014Primary
Full dose LSD(experimental)0853.14.7
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
2014Primary
Full dose LSD(experimental)78
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
2014Primary
Full dose LSD(experimental)60841.53.20.021
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
2014Primary
Full dose LSD(experimental)365936.18.3
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
2014Primary
Active placebo LSD(active_comparator)0347.77.7
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
2014Primary
Active placebo LSD(active_comparator)60351.75.30.021
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
2014Primary
Active placebo LSD(active_comparator)60336.012.50.021
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
2016Secondary
Psilocybin(experimental)01270.15.8
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
2016Secondary
Psilocybin(experimental)71240.614.2
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
2016Secondary
Psilocybin(experimental)901254.814.5

Papers Using STAI

Quick Facts

Full Name
State-Trait Anxiety Inventory
Domain
Anxiety
Papers Indexed
19
Score Range
2080
Interpretation
Lower = better
Unit
points
Reference
Visit
All Measures